CERO.OQBCero Therapeutics Holdings, INC
10-K/A: CERo Therapeutics Files Amendment to 10-K to Include Part III Information
Sentiment:
Form 10-K/A (Amendment No. 1)
CERo Therapeutics Holdings files an amendment to its annual report to include information required by Part III of Form 10-K, covering details about directors, executive officers, compensation, and corporate governance.
Capital raiseIn February 2024, the company issued and sold an aggregate of 10,039 shares of Series A Preferred Stock, 6,127 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised.On February 7, 2025, the company issued and sold 300,000 shares of its Common Stock and 2,251,020 Pre-Funded Warrants to purchase 2,251,020 shares of its Common Stock together with 2,551,020 February 2025 Common Warrants to purchase 2,551,020 shares of Common Stock.
Summary
- CERo Therapeutics Holdings, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K to include information required by Part III (Items 10, 11, 12, 13, and 14).
- The original annual report was filed on April 15, 2025.
- The amendment includes details about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
- The company's board of directors consists of six members divided into three classes with staggered three-year terms.
- Key executive officers include Chris Ehrlich (Chairman and CEO), Andrew Al Kucharchuk (CFO), and Kristen Pierce, Ph.D. (Chief Development Officer).
- The company has adopted a code of business conduct and ethics applicable to its directors, officers, and employees.
- The company's compensation committee reviews and approves executive compensation, considering market data and performance.
- The company maintains equity incentive plans, including the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan.
- The company's independent public accounting firm is Wolf & Company, P.C.
- The company incurred $511,500 in fees from Wolf & Company, P.C. for the audit of the consolidated financial statements and for other services provided during the year ended December 31, 2024.
Sentiment
Score: 6
Explanation: The document is primarily factual and descriptive, with a neutral tone. It provides necessary disclosures but does not express strong positive or negative sentiment.
Positives
- The company has a staggered board, which can provide stability.
- The company has independent directors on its audit, compensation, and nominating and corporate governance committees.
- The company has adopted a code of business conduct and ethics.
- The company maintains a 401(k) plan for eligible employees.
- The company has a Compensation Recovery Policy in place.
Negatives
- The company has had multiple changes in its CEO and CFO positions in 2024.
- The company's staggered board may delay or prevent a change in control.
- The company's Certificate of Incorporation allows directors to be removed only for cause by a supermajority vote.
- The company's insider trading policy expressly prohibits derivative transactions of the company's stock by executive officers, directors and employees.
Risks
- The company's success depends on attracting and retaining qualified personnel.
- The company's compensation policies or programs could encourage excessive risk-taking.
- The company's reliance on key personnel could be a risk if they were to leave.
- The company's insider trading policy expressly prohibits derivative transactions of the company's stock by executive officers, directors and employees, which could limit their ability to manage their investment risk.
Future Outlook
The company anticipates annually reviewing the compensation of its employees, including its executive officers.
Industry Context
The document provides standard disclosures related to executive compensation, corporate governance, and related party transactions, which are common in the biopharmaceutical industry.
Comparison to Industry Standards
- Executive compensation arrangements, including base salaries, bonus opportunities, and equity compensation, are typical for companies in the biotechnology industry.
- The use of independent compensation consultants to advise on executive compensation matters is a common practice among publicly traded companies.
- The company's equity incentive plans are similar to those offered by other companies in the industry to attract, retain, and motivate employees.
- The company's corporate governance practices, such as having independent directors and committees, are consistent with Nasdaq listing requirements and industry best practices.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Brian G. Atwood | Chris Ehrlich | October 1, 2024 | Resignation |
| Chief Financial Officer | Charles Carter | Andrew Al Kucharchuk | October 1, 2024 | Resignation |
| Chief Technology Officer | Daniel Corey | N/A | September 23, 2024 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Structure | The board of directors is divided into three classes with staggered three-year terms. | N/A | May delay or prevent a change in control. |
| Director Independence | The board of directors has determined that Mr. Byrnes, Ms. LaPorte, Dr. Rolfe and Mr. Patel are independent directors. | N/A | Ensures independent oversight of management. |
| Code of Conduct | The company has adopted a code of business conduct and ethics. | N/A | Promotes ethical behavior and compliance with laws and regulations. |
Related Party Transactions
- In February 2024, the company issued Series A Preferred Stock to related parties, including Daniel Corey, Atwood-Edminster Trust dtd 4-2-2000, Chris Ehrlich, and Phoenix Biotech Sponsor, LLC.
- Brian Atwood, one of the company's directors, purchased an aggregate of 510,200 Pre-Funded Warrants and accompanying February 2025 Common Warrants to purchase 510,200 shares of Common Stock for a total purchase price of approximately $1 million in the February 2025 registered direct offering.
Stakeholder Impact
- The information in this amendment provides stakeholders with important details about the company's leadership, governance, and compensation practices.
- The disclosures regarding related party transactions help stakeholders assess potential conflicts of interest.
- The information about equity incentive plans and security ownership provides insights into the alignment of interests between management and shareholders.
Next Steps
- The company will file a proxy statement in connection with its 2026 annual meeting of stockholders within 120 days after the end of the fiscal year ended December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| March 3, 2020 | Legacy CERo entered into a collaboration and option agreement. |
| October 5, 2021 | Date of Warrant Agreement, by and between Phoenix Biotech Acquisition Corp. and Continental Stock Transfer & Trust Company. |
| January 1, 2023 | Date from which related party transactions are disclosed. |
| March 3, 2023 | Collaboration Agreement terminated. |
| June 4, 2023 | Business Combination Agreement date. |
| December 31, 2023 | Fiscal year end for PBAX audit fees. |
| February 5, 2024 | Amendment No. 1 to the Business Combination Agreement date. |
| February 6, 2024 | Phoenix Biotech Acquisition Corp. filed a Current Report on Form 8-K with the Securities and Exchange Commission. |
| February 8, 2024 | The stockholders approved the 2024 Plan and 2024 ESPP. |
| February 13, 2024 | Amendment No. 2 to the Business Combination Agreement date. |
| February 14, 2024 | Closing of the Business Combination. |
| March 25, 2024 | Board of directors approved the compensation for non-employee directors for 2024. |
| March 26, 2024 | Employment agreements entered into with Mr. Atwood and Mr. Carter. |
| March 28, 2024 | Employment agreement entered into with Dr. Corey. |
| March 29, 2024 | Securities Purchase Agreement date. |
| April 2, 2024 | CERo Therapeutics Holdings, Inc. filed the Annual Report on Form 10-K with the Securities and Exchange Commission. |
| April 15, 2024 | The Company issued options in April 2024. |
| April 30, 2024 | Special meeting of stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options. |
| September 23, 2024 | Dr. Corey resigned from his position as Chief Technology Officer. |
| September 25, 2024 | Securities Purchase Agreement date. |
| September 26, 2024 | Registration Rights Agreement date. |
| September 30, 2024 | Mr. Atwood and Mr. Carter resigned from their positions as Chief Executive Officer and Chief Financial Officer, respectively. |
| October 1, 2024 | Mr. Ehrlich became Chief Executive Officer. |
| October 2, 2024 | The Company issued options in October 2024. |
| November 8, 2024 | Common Stock Purchase Agreement date. |
| November 11, 2024 | Special meeting of stockholders approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options. |
| December 31, 2024 | Fiscal year end. |
| January 1, 2025 | The number of shares reserved under the 2024 Plan was increased by 5% of the fully diluted shares of our common stock on the immediately preceding December 31, or 189,701 shares. |
| February 5, 2025 | Placement Agency Agreement date. |
| February 7, 2025 | We issued and sold 300,000 shares of our Common Stock and 2,251,020 Pre-Funded Warrants to purchase 2,251,020 shares of our Common Stock together with 2,551,020 February 2025 Common Warrants to purchase 2,551,020 shares of Common Stock. |
| February 2025 | The board of directors increased Mr. Ehrlichs monthly salary to $40,000 per month and, on March 4, 2025, granted to him options to purchase up to 238,971 shares of Common Stock. |
| April 1, 2025 | As of April 1, 2025, the board of directors have granted an aggregate of 471,199 option awards under the 2024 Plan, leaving no shares reserved for future issuance under the 2024 Plan. |
| April 11, 2025 | Date for beneficial ownership of common stock. |
| April 15, 2025 | CERo Therapeutics Holdings, Inc. filed the Annual Report on Form 10-K with the Securities and Exchange Commission. |
| April 24, 2025 | The registrant had 5,578,791 shares of common stock outstanding. |
| April 28, 2025 | Date of certifications of Principal Executive Officer and Principal Financial Officer. |
Keywords
executive compensation, corporate governance, directors, officers, equity incentive plan, audit fees, Form 10-K, CERo Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.